Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB.
Diabetes Obes Metab. 2023 Jul;25(7):1932-1941. doi: 10.1111/dom.15058. Epub 2023 Apr 11.
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
Marx N, Husain M, Lehrke M, Verma S, Sattar N.
Circulation. 2022 Dec 13;146(24):1882-1894. doi: 10.1161/CIRCULATIONAHA.122.059595. Epub 2022 Dec 12.
Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?
Ishii H.
J Diabetes Investig. 2022 Jul;13(7):1114-1121. doi: 10.1111/jdi.13799. Epub 2022 Apr 18.
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.
Kaur R, Kaur M, Singh J.
Cardiovasc Diabetol. 2018 Aug 31;17(1):121. doi: 10.1186/s12933-018-0763-3.
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.
Yang YS, Kim HL, Kim SH, Moon MK.
Diabetes Metab J. 2023 Jan;47(1):1-9. doi: 10.4093/dmj.2022.0448. Epub 2023 Jan 20.
Subclinical Atherosclerosis in Young Adult Population with First Degree Relatives of Type 2 Diabetes Mellitus.
Abdaly MS, Azizi MS, Wijaya IP, Nugroho P, Purnamasari D.
Acta Med Indones. 2019 Apr;51(2):169-176.
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB.
Circulation. 2016 Jun 14;133(24):2459-502. doi: 10.1161/CIRCULATIONAHA.116.022194.
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC.
Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24.
Role of neutrophils in type 2 diabetes and associated atherosclerosis.
Keeter WC, Moriarty AK, Galkina EV.
Int J Biochem Cell Biol. 2021 Dec;141:106098. doi: 10.1016/j.biocel.2021.106098. Epub 2021 Oct 13.
Neuroprotective Effect of SGLT2 Inhibitors.
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P.
Molecules. 2021 Nov 28;26(23):7213. doi: 10.3390/molecules26237213.
